Clearside Biomedical
CLSD
CLSD was delisted on the 28th of November, 2025.
45 hedge funds and large institutions have $6.82M invested in Clearside Biomedical in 2023 Q3 according to their latest regulatory filings, with 4 funds opening new positions, 8 increasing their positions, 13 reducing their positions, and 13 closing their positions.
6% more call options, than puts
Call options by funds: $89K | Put options by funds: $84K
0.09% less ownership
Funds ownership: 0.93% → 0.84% (-0.09%)
17% less funds holding
Funds holding: 54 → 45 (-9)
29% less capital invested
Capital invested by funds: $9.62M → $6.82M (-$2.81M)
38% less repeat investments, than reductions
Existing positions increased: 8 | Existing positions reduced: 13
69% less first-time investments, than exits
New positions opened: 4 | Existing positions closed: 13
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Royal Bank of Canada
Toronto,
Ontario, Canada
|
+$45.1K |
| 2 |
XT
XTX Topco
George Town,
Cayman Islands
|
+$27.8K |
| 3 |
CAPTRUST Financial Advisors
Raleigh,
North Carolina
|
+$26.2K |
| 4 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
+$21.9K |
| 5 |
Wealth Enhancement Advisory Services
Plymouth,
Minnesota
|
+$20.2K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
CG
Carmignac Gestion
Paris,
France
|
-$270K |
| 2 |
TC
TownSquare Capital
Provo,
Utah
|
-$123K |
| 3 |
BCM
Bridgeway Capital Management
Houston,
Texas
|
-$105K |
| 4 |
Renaissance Technologies
New York
|
-$64K |
| 5 |
BlackRock
New York
|
-$50.6K |
CLSD Hedge Fund Activity: Q3 2023 in Review
45 of the 6,301 institutional investors tracked by Wall St. Rank reported a position in Clearside Biomedical (CLSD) for Q3 2023, worth a combined $6.82M — down 29% from $9.62M a quarter earlier.
Sellers outnumbered buyers: 13 funds closed out of CLSD and 4 opened new positions — a net loss of 9 holders — while 13 trimmed existing stakes and 8 added.
The largest buyer was Royal Bank of Canada, adding an estimated $45.1K. The largest seller was Carmignac Gestion, cutting an estimated $270K.
- 45 institutional investors held Clearside Biomedical (CLSD) as of Q3 2023, down from 54 in Q2 2023.
- Funds reported $6.82M of Clearside Biomedical stock for Q3 2023, down 29% quarter-over-quarter.
- 4 funds opened new Clearside Biomedical positions in Q3 2023 and 13 closed out, a net change of -9 holders.
- The largest Clearside Biomedical buyer in Q3 2023 was Royal Bank of Canada, an estimated $45.1K added.
- The largest Clearside Biomedical seller in Q3 2023 was Carmignac Gestion, an estimated $270K sold.
Based on aggregated 13F filings for Q3 2023.